About

GEOPLAN NUTRACEUTICALS was founded in Athens, Greece, in 2019 by a team of esteemed Greek scientists. Their firm belief in the therapeutic value of food supplements as a fundamental component of modern preventive healthcare and disease management, prompted them to pursue the development of advanced, highly effective formulations. With strong focus on efficacy and quality, the development of FORTIUS product line was driven by the urge to address health challenges encountered in everyday life. These innovative formulations are scientifically substantiated, designed with synergistic or cumulative ingredient interactions, and produced in optimal ratios based on comprehensive literature reviews. To uphold highest quality standards, Geoplan has partnered with certified manufacturing facility and analytical laboratories that meet stringent pharmaceutical standards, using only premium-grade raw materials.

Solution & Product

Our firm belief in the therapeutic value of food supplements as a fundamental component of modern preventive healthcare and disease management, prompted us to pursue the development of advanced, highly effective formulations for optimal results. These innovative formulations are scientifically substantiated, designed with synergistic or cumulative ingredient interactions, and produced in optimal ratios based on comprehensive literature reviews. Leveraging our extensive expertise in pharmaceutical research, development, manufacturing, sales and marketing, the founding team envisioned the creation of innovative, unique products with guaranteed, superior quality standards. Our goal is to address the evolving health and wellness needs and challenges of modern lifestyles, by offering solutions that integrate natural ingredients with cutting edge scientific advancements, thus enhancing consumers’ well-being, vitality, and longevity.

Innovation & Scalability

Geoplan is distinguished by the development of unique formulations and its continuous pursuit of innovative solutions. All Geoplan products are formulated as oral dispersible tablets, providing enhanced convenience as they eliminate difficulties associated with swallowing. They ensure superior ingredients’ absorption, as tablets gradually dissolve in the mouth, enabling rapid bioavailability and increased effectiveness. New product development is guided by the selection of unique ingredient combinations, with a primary emphasis on the synergistic action of active compounds. This approach is designed to maximize the efficacy of the final product, ensuring market differentiation and high value-added products. Cutting-edge technologies and innovative concepts are continuously evaluated in order to enhance the bioavailability of active ingredients, while the most suitable raw materials are carefully selected to achieve this objective. Furthermore, a comprehensive analysis of market trends and consumer health needs informs the product development process, enabling the design of scientifically validated solutions that align with contemporary health and wellness demands. The distinctiveness of our formulations is safeguarded through patents issued by the Hellenic Industrial Property Organization (OBI) – the exclusive authority in Greece responsible for the protection of intellectual property in the field of innovations.

Traction & achievements

Geoplan Nutraceuticals, established in 2019, has achieved several significant milestones that underscore its commitment to innovation and quality in the nutraceutical industry.​ Key Milestones: 2019: Company Inception Founded by experienced health professionals with a vision to develop specialized nutraceutical products, focusing on food supplements. Product Development Launched a range of innovative products, Fortius D3+B12 series (2021) Fortius PRO (2022), Fortius MAG+ (2023) and Fortius PRO F.A.S.T. (2024), designed to support and maintain health in daily life. ​ Research Collaboration Conducted a multicenter, randomized controlled trial in Greece from October to December 2024, evaluating the effectiveness of Fortius D3+B12. Strategic Partnerships All products are manufactured at one of the most advanced production facilities in Greece. Collaborated with The Coachultants for strategic direction and communication planning.

Team & Why Us

Thanasis Zlatanos, Co-owner, Chemist, MSc. Holding an MSc in Marketing & Product Management, with experience in promoting Greek generic pharmaceuticals as medical representative. He specializes in identifying the evolving medical community needs. Leonidas Chatziantoniou, Co-owner, Biologist, MSc. A Biologist who has worked both in pharmaceutical research and commercial operations within the Greek pharmaceutical industry. He focuses on the strategic development of novel, innovative product formulations. George Patsis Chemist, Co-owner, Chemist PhD. with a strong academic background, possessing extensive experience across all stages of pharmaceutical manufacturing. Responsible for Quality Assurance and implementing high quality standards. Kalliopi Alexiou, Biologist, BSc., with experience in pharmaceutical QC, currently working as an R&D assistant at Geoplan, managing regulatory affairs and liaising with authorities for the notification of food supplements. GEOPLAN is a specialty, science-first regional brand, differentiated from commodity supplement players. GEOPLAN is building growth on scientific legitimacy, not mass marketing. Its success hinges on converting scientific credibility into real regional market traction. We invest in clinical proof, expand thoughtfully, and keep strict quality, so that we can carve out a premium niche.

Funding Needs

This business plan outlines the strategic funding needs to support GEOPLAN’s next growth phase (2025–2030), focusing on product innovation, clinical validation, regulatory expansion, and digital-first market penetration. Total Funding Requirement Summary: Category Estimate (€) Clinical R&D 50,000 – 100,000 Product Development 200,000 – 300,000 Branding & Marketing 100,000 – 200,000 Regulatory Compliance 50,000 – 60,000 Team Expansion 300,000 – 500,000 Working Capital 200,000 – 300,000 Manufacturing & Inventory 1,500,000 – 2,000,000 Total 2.4M – 3.46M